INVEGA SUSTENNA® is approved for the treatment of schizoaffective disorder

Safety and Tolerability of INVEGA SUSTENNA® vs Commonly Prescribed Oral Antipsychotics1,2*

Select treatment-emergent adverse events (TEAEs) in 5% of patients in any INVEGA SUSTENNA® group and at least twice that of the oral group2
A graph illustrating potential INVEGA SUSTENNA® (paliperidone palmitate) adverse reactions and other tolerability information, comparative efficacy study

*The 7 oral antipsychotics (included in the comparative arm) account for 74% of oral schizophrenia treatment during the study period.3

Data from randomization until end of randomly assigned treatment (28 days after last injection of INVEGA SUSTENNA® or 1 day after last dose of oral antipsychotic).

The study was not powered to compare the efficacy of INVEGA SUSTENNA® with that of individual oral antipsychotics.

No new safety signals for INVEGA SUSTENNA® were observed1

  • Percentage of patients who discontinued due to AEs was 11.9% in the INVEGA SUSTENNA® group and 7.8% in the oral antipsychotic group2
  • The 5 most common AEs in the INVEGA SUSTENNA® group were injection-site pain (18.6%), insomnia (16.8%), weight increased (11.9%), akathisia (11.1%), and anxiety (10.6%)2
  • There were no unexpected safety concerns related to vital signs, physical examination findings, or clinical laboratory test results with INVEGA SUSTENNA®2

View comparative efficacy study data

References: 1. INVEGA SUSTENNA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; March 2018. 2. Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board–blinded 15-month study. J Clin Psychiatry. 2015;76(5):554-561. 3. Data on file. Janssen Pharmaceuticals, Inc., Titusville, NJ. IMS Real-World Data. May 2010-December 2013. 

Content area 1.2